Ultime notizie per Bausch & Lomb (NYSE:BLCO) Azioni

Bausch & Lomb

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Bausch & Lomb Corp

News

Stock Split

FOXO

Foxo Technologies Announces 1 For 10 Reverse Stock Split, Effective April 28, 2025

Zoom Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) shares are trading higher Thursday following a significant global outage that temporarily disabled key parts of Zoom's platform, including video calls,<a href="https://www.benzinga.com/quote/ZM/news"> its web portal and app.</a>
What To Know: The outage, which occurred on Wednesday afternoon, was confirmed by the company and tracked in real time by Downdetector.com, according to Reuters. At its peak, over 67,000 users reported problems accessing Zoom&#8217;s services, with disruptions affecting both U.S. and international users. The company did not offer a detailed technical explanation but confirmed on social media that full service had been restored.
The brief disruption likely reminded investors of the platform's broad user base and the technical risks that come with operating such a widely used service. But, the lack of a sharp sell-off suggests the market viewed the outage as temporary and not materially damaging to Zoom&#8217;s longer-term operations or reputation. Still, a repeat of such widespread failures could draw more scrutiny given how reliant businesses, schools and government agencies have become on Zoom for communication.
<h1 class="wp-block-heading">Will Zoom Shares Go Up?</h1>
When trying to assess whether or not Zoom will trade higher from current levels, it's a good idea to take a look at analyst forecasts.
Wall Street analysts have an average 12 month price target of $85.25 on Zoom. The &#8220;Street high&#8221; target is currently at $97 and the &#8220;Street low&#8221; target is $7. Of all the analysts covering Zoom Communications, five have positive ratings, seven have neutral ratings and none have negative ratings.
In the last month, four analysts have adjusted price targets. Here's a look at recent price target changes <a href="https://www.benzinga.com/quote/ZM/analyst-ratings">[Analyst Ratings]</a>. Benzinga also tracks Wall Street's most accurate analysts. Check out how analysts covering Zoom have performed in recent history.
Stocks don't move in a straight line. The average stock market return is approximately 10% per year. Zoom is down 12.37% year-to-date. The average analyst price target suggests the stock could have further upside ahead.
For a broad overview of everything you need to know about Zoom, visit <a href="https://www.benzinga.com/quote/ZM">here</a>. If you want to go above and beyond, there's no better tool to help you do just that than <a href="https://pro.benzinga.com/">Benzinga Pro</a>. Start your free trial today.
ZM Price Action: Zoom shares closed Thursday up 0.41% at $71.49 at the time of writing, according to<a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"> Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0417"><img loading="lazy" decoding="async" width="1024" height="566" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17163518/Screenshot-2025-04-17-at-16.33.21-1024x566.png" alt="" class="wp-image-877718" style="width:425px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17163518/Screenshot-2025-04-17-at-16.33.21-1024x566.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17163518/Screenshot-2025-04-17-at-16.33.21-300x166.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17163518/Screenshot-2025-04-17-at-16.33.21-768x425.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17163518/Screenshot-2025-04-17-at-16.33.21.png 1457w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44875406/hell-be-out-if-i-ask-him-can-trumps-threat-to-oust-powell-shake-the-fed">&#8216;He&#8217;ll Be Out&#8230; If I Ask Him&#8217;: Can Trump&#8217;s Threat To Oust Powell Shake The Fed?</a></li>
</ul>
Photo: Shutterstock.

Movers

What's Going On With Zoom Shares Today?

Analysts' ratings for Take-Two Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) over the last quarter vary from bullish to bearish, as provided by 11 analysts.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $223.45, a high estimate of $270.00, and a low estimate of $170.00. Observing a 14.71% increase, the current average has risen from the previous average price target of $194.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1744923677_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Take-Two Interactive. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Brian Nowak &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Overweight &#x7C; $210.00&#x7C;$215.00 &#x7C; 
&#x7C;Edward Woo &#x7C;Ascendiant Capital &#x7C;Raises &#x7C;Buy &#x7C; $270.00&#x7C;$172.00 &#x7C; 
&#x7C;Wyatt Swanson &#x7C;DA Davidson &#x7C;Announces &#x7C;Buy &#x7C; $250.00&#x7C;- &#x7C; 
&#x7C;Michael Pachter &#x7C;Wedbush &#x7C;Maintains &#x7C;Outperform &#x7C; $215.00&#x7C;$215.00 &#x7C; 
&#x7C;Mike Hickey &#x7C;Benchmark &#x7C;Raises &#x7C;Buy &#x7C; $225.00&#x7C;$210.00 &#x7C; 
&#x7C;Eric Sheridan &#x7C;Goldman Sachs &#x7C;Raises &#x7C;Buy &#x7C; $230.00&#x7C;$205.00 &#x7C; 
&#x7C;Andrew Marok &#x7C;Raymond James &#x7C;Raises &#x7C;Outperform &#x7C; $220.00&#x7C;$190.00 &#x7C; 
&#x7C;Clay Griffin &#x7C;MoffettNathanson &#x7C;Raises &#x7C;Neutral &#x7C; $170.00&#x7C;$156.00 &#x7C; 
&#x7C;Christopher Schoell &#x7C;UBS &#x7C;Raises &#x7C;Buy &#x7C; $230.00&#x7C;$175.00 &#x7C; 
&#x7C;Martin Yang &#x7C;Oppenheimer &#x7C;Raises &#x7C;Outperform &#x7C; $215.00&#x7C;$190.00 &#x7C; 
&#x7C;Drew Crum &#x7C;Stifel &#x7C;Raises &#x7C;Buy &#x7C; $223.00&#x7C;$220.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Take-Two Interactive. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Take-Two Interactive compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Take-Two Interactive's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Take-Two Interactive's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/TTWO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Take-Two Interactive analyst ratings.</a>
<h2>Discovering Take-Two Interactive: A Closer Look</h2>
Take-Two is one of the largest global developers and publishers of video games, with labels including Rockstar, 2K, and Zynga. Grand Theft Auto is the firm's biggest franchise, accounting for about 30% of total sales for the past decade. NBA 2K is the industry's dominant basketball video game, with Take-Two releasing a new version annually. Other notable franchises include Red Dead Redemption, Borderlands, and Civilization. Typically, more than three quarters of the firm's sales are from in-game spending, with the remainder coming from initial game sales. Since acquiring Zynga in 2022, mobile makes up about half of total sales.
<h3>Unraveling the Financial Story of Take-Two Interactive</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Decline in Revenue: Over the 3M period, Take-Two Interactive faced challenges, resulting in a decline of approximately -0.48% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Communication Services sector.
Net Margin: Take-Two Interactive's net margin excels beyond industry benchmarks, reaching -9.21%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Take-Two Interactive's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -2.18%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Take-Two Interactive's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -0.97%, the company showcases efficient use of assets and strong financial health.
Debt Management: Take-Two Interactive's debt-to-equity ratio is below the industry average at 0.72, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

TTWO

Deep Dive Into Take-Two Interactive Stock: Analyst Perspectives (11 Ratings)

4 analysts have shared their evaluations of Applied Industrial Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIT#NYSE">AIT</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $276.25, with a high estimate of $290.00 and a low estimate of $265.00. Observing a downward trend, the current average is 3.49% lower than the prior average price target of $286.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1744923670_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Applied Industrial Techs. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Chris Dankert &#x7C;Loop Capital &#x7C;Lowers &#x7C;Buy &#x7C; $290.00&#x7C;$320.00 &#x7C; 
&#x7C;Ken Newman &#x7C;Keybanc &#x7C;Lowers &#x7C;Overweight &#x7C; $275.00&#x7C;$325.00 &#x7C; 
&#x7C;David Manthey &#x7C;Baird &#x7C;Raises &#x7C;Outperform &#x7C; $275.00&#x7C;$250.00 &#x7C; 
&#x7C;Sam Darkatsh &#x7C;Raymond James &#x7C;Raises &#x7C;Outperform &#x7C; $265.00&#x7C;$250.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Applied Industrial Techs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Applied Industrial Techs compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Applied Industrial Techs's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Applied Industrial Techs's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AIT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Applied Industrial Techs analyst ratings.</a>
<h2>Discovering Applied Industrial Techs: A Closer Look</h2>
Applied Industrial Technologies Inc is a distributor of industrial products to the maintenance, repair, and operations market and the original equipment manufacturing industry. Further, the company provides engineering and design services for industrial and fluid power applications. The products include bearings, power transmission components, fluid power components and systems, industrial rubber products, linear motion components, safety products, oilfield supplies, and other industrial and maintenance supplies. The company's reportable segments are; Service Center Based Distribution which derives key revenue, and Engineered Solutions. Geographically, the company derives its key revenue from the United States and the rest from Canada and other countries.
<h3>Financial Milestones: Applied Industrial Techs's Journey</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Applied Industrial Techs's revenue growth over a period of 3M has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -0.39%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: Applied Industrial Techs's net margin is impressive, surpassing industry averages. With a net margin of 8.69%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Applied Industrial Techs's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 5.26%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Applied Industrial Techs's ROA excels beyond industry benchmarks, reaching 3.09%. This signifies efficient management of assets and strong financial health.
Debt Management: Applied Industrial Techs's debt-to-equity ratio is below the industry average. With a ratio of 0.32, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Applied Industrial Techs Stands With Analysts

Digital Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>) underwent analysis by 12 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $195.5, along with a high estimate of $220.00 and a low estimate of $139.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 2.03%. 
<img src="https://www.benzinga.com/files/images/story/2025/1744923659_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of Digital Realty Trust's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Michael Rollins &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $174.00&#x7C;$188.00 &#x7C; 
&#x7C;Omotayo Okusanya &#x7C;Mizuho &#x7C;Lowers &#x7C;Outperform &#x7C; $177.00&#x7C;$211.00 &#x7C; 
&#x7C;Brendan Lynch &#x7C;Barclays &#x7C;Lowers &#x7C;Underweight &#x7C; $139.00&#x7C;$142.00 &#x7C; 
&#x7C;Anthony Hau &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $185.00&#x7C;$201.00 &#x7C; 
&#x7C;Greg Miller &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $220.00&#x7C;$220.00 &#x7C; 
&#x7C;Maher Yaghi &#x7C;Scotiabank &#x7C;Announces &#x7C;Sector Outperform&#x7C; $208.00&#x7C;- &#x7C; 
&#x7C;Greg Miller &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $220.00&#x7C;$220.00 &#x7C; 
&#x7C;Richard Choe &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $190.00&#x7C;$185.00 &#x7C; 
&#x7C;Greg Miller &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $220.00&#x7C;$220.00 &#x7C; 
&#x7C;Eric Luebchow &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $185.00&#x7C;$210.00 &#x7C; 
&#x7C;Greg Miller &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $220.00&#x7C;$220.00 &#x7C; 
&#x7C;Maher Yaghi &#x7C;Scotiabank &#x7C;Raises &#x7C;Sector Perform &#x7C; $208.00&#x7C;$178.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Digital Realty Trust. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Digital Realty Trust compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Digital Realty Trust's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Digital Realty Trust's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/DLR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Digital Realty Trust analyst ratings.</a>
<h2>All You Need to Know About Digital Realty Trust</h2>
Digital Realty owns and operates over 300 data centers worldwide. It has nearly 40 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to "cold shells," where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has de-emphasized cold shells and now primarily provides higher-level service to tenants, which outsource their related IT needs to Digital. The company operates as a real estate investment trust.
<h3>Digital Realty Trust's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Over the 3M period, Digital Realty Trust showcased positive performance, achieving a revenue growth rate of 4.84% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Digital Realty Trust's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 12.49%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Digital Realty Trust's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 0.87%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Digital Realty Trust's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.4%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.87.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Digital Realty Trust In The Eyes Of 12 Experts

In the current market session, UBS Gr Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBS#NYSE">UBS</a>) price is at $27.94, after a 0.47% spike. However, over the past month, the stock decreased by 15.31%, and in the past year, by 0.43%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1744923653_0.png" alt="Past Year Chart" />

<h3>UBS Gr P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 31.5 in the Capital Markets industry, UBS Gr Inc. has a lower P/E ratio of 18.3. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1744923653_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

Price Over Earnings Overview: UBS Gr

5 analysts have expressed a variety of opinions on Vir Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIR#NASDAQ">VIR</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $58.2, a high estimate of $110.00, and a low estimate of $19.00. This current average represents a 0.68% decrease from the previous average price target of $58.60. 
<img src="https://www.benzinga.com/files/images/story/2025/1744923641_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of Vir Biotechnology by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Paul Choi &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Buy &#x7C; $21.00&#x7C;$28.00 &#x7C; 
&#x7C;Gena Wang &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $31.00&#x7C;$26.00 &#x7C; 
&#x7C;Patrick Trucchio &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $110.00&#x7C;$110.00 &#x7C; 
&#x7C;Joseph Stringer &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $19.00&#x7C;$19.00 &#x7C; 
&#x7C;Patrick Trucchio &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $110.00&#x7C;$110.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Vir Biotechnology. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Vir Biotechnology compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Vir Biotechnology's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Vir Biotechnology's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/VIR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Vir Biotechnology analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Vir Biotechnology: A Closer Look</h2>
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
<h3>A Deep Dive into Vir Biotechnology's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Positive Revenue Trend: Examining Vir Biotechnology's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 17.45% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Vir Biotechnology's net margin excels beyond industry benchmarks, reaching -927.37%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Vir Biotechnology's ROE stands out, surpassing industry averages. With an impressive ROE of -8.75%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -7.22%, the company showcases effective utilization of assets.
Debt Management: Vir Biotechnology's debt-to-equity ratio is below the industry average at 0.09, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

5 Analysts Have This To Say About Vir Biotechnology

7 analysts have shared their evaluations of Edgewell Personal Care (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPC#NYSE">EPC</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $34.29, with a high estimate of $43.00 and a low estimate of $28.00. Observing a downward trend, the current average is 10.09% lower than the prior average price target of $38.14. 
<img src="https://www.benzinga.com/files/images/story/2025/1744923621_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Edgewell Personal Care among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Peter Grom &#x7C;UBS &#x7C;Raises &#x7C;Neutral &#x7C; $32.00&#x7C;$31.00 &#x7C; 
&#x7C;Lauren Lieberman &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $28.00&#x7C;$30.00 &#x7C; 
&#x7C;Susan Anderson &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Buy &#x7C; $40.00&#x7C;$53.00 &#x7C; 
&#x7C;Lauren Lieberman &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $30.00&#x7C;$33.00 &#x7C; 
&#x7C;Nik Modi &#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $43.00&#x7C;$48.00 &#x7C; 
&#x7C;Chris Carey &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $35.00&#x7C;$37.00 &#x7C; 
&#x7C;Dara Mohsenian &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Underweight &#x7C; $32.00&#x7C;$35.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Edgewell Personal Care. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Edgewell Personal Care compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Edgewell Personal Care's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Edgewell Personal Care's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EPC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Edgewell Personal Care analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Edgewell Personal Care: A Closer Look</h2>
Edgewell Personal Care Co is a personal-care company. The operating segments of the company include Wet Shave, Sun and Skin Care and Feminine Care. Some of the brands offered by the company include Edge, Skintimate, Personna, Schick, Carefree, Playtex, Banana Boat and Hawaiian Tropic. It derives a majority of its revenue from the United States.
<h3>Understanding the Numbers: Edgewell Personal Care's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Challenges: Edgewell Personal Care's revenue growth over 3M faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -2.15%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Staples sector.
Net Margin: Edgewell Personal Care's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -0.44%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Edgewell Personal Care's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.14% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Edgewell Personal Care's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.06%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Edgewell Personal Care's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.98.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Edgewell Personal Care: Insights From 7 Analyst Reviews

Across the recent three months, 6 analysts have shared their insights on Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $57.0, with a high estimate of $65.00 and a low estimate of $50.00. Observing a downward trend, the current average is 17.39% lower than the prior average price target of $69.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1744923614_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Bruker among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Brandon Couillard &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $60.00&#x7C;$75.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $50.00&#x7C;$60.00 &#x7C; 
&#x7C;Patrick Donnelly &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $50.00&#x7C;$75.00 &#x7C; 
&#x7C;Daniel Arias &#x7C;Stifel &#x7C;Lowers &#x7C;Hold &#x7C; $57.00&#x7C;$70.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $60.00&#x7C;$65.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $65.00&#x7C;$69.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Bruker. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Bruker compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Bruker's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Bruker's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BRKR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Bruker analyst ratings.</a>
<h2>Delving into Bruker's Background</h2>
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
<h3>Key Indicators: Bruker's Financial Health</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Bruker showcased positive performance, achieving a revenue growth rate of 14.64% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Bruker's net margin excels beyond industry benchmarks, reaching 1.4%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Bruker's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 0.76%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Bruker's ROA excels beyond industry benchmarks, reaching 0.23%. This signifies efficient management of assets and strong financial health.
Debt Management: Bruker's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.26, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BRKR

A Glimpse Into The Expert Outlook On Bruker Through 6 Analysts

Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) has outperformed the market over the past 10 years by 9.42% on an annualized basis producing an average annual return of 19.01%. Currently, Cencora has a market capitalization of $55.54 billion. 
Buying $1000 In COR: If an investor had bought $1000 of COR stock 10 years ago, it would be worth $5,708.54 today based on a price of $286.70 for COR at the time of writing.
<h3>Cencora's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744923611_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Cencora Stock In The Last 10 Years

Cryptocurrencies are trading slightly up on Thursday as traditional financial markets closed out a low-volatility week.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td> $85,070</td>
<td>+0.9%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td> $1,585</td>
<td>+0.6%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td> $134.8</td>
<td>+2.2%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td> $2.07</td>
<td>-1.0%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.1565</td>
<td>+1.6%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00001177</td>
<td>+0.6%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul>
<li>IntoTheBlock data shows large transaction volume decreasing by 21% and daily active addresses falling by 1.6%. Transactions greater than $100,000 are down from 9,765 to 9,314 in a single day. Exchanges netflows are up by 52.8%.</li>
<li>Coinglass data reports 70,013 traders were liquidated in the past 24 hours for $138.74 million.</li>
</ul>
Notable Developments:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44856786/bhutan-flexes-hydropower-for-bitcoin-mining-explores-sale-of-green-coins">Bhutan Flexes Hydropower For Bitcoin Mining, Explores Sale Of &#8216;Green&#8217; Coins</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44858748/millennium-managements-bitcoin-and-ethereum-etfs-purchased-in-q4-suffer-22-7-million-loss-amid-crypto-slump">Millennium Management&#8217;s Bitcoin And Ethereum ETFs Purchased In Q4 Suffer $22.7 Million Loss Amid Crypto Slump</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44869153/unrealized-bitcoin-losses-hit-all-time-high-glassnode-says-bear-market-signs">Unrealized Bitcoin Losses Hit All-Time High, Glassnode Says: Bear Market Signs?</a></li>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44869664/coinbase-global-goes-from-boom-to-bust-amid-crypto-winter-analyst-trims-q1-estimates">Coinbase Global Goes From Boom To Bust Amid Crypto Winter, Analyst Trims Q1 Estimates</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44867243/binance-advising-nations-on-strategic-bitcoin-reserves-crypto-regulation-report">Binance Advising Nations On Strategic Bitcoin Reserves, Crypto Regulation: Report</a></li>
</ul>
Top Losers:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Mantra (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/om/usd">OM</a>)</td>
<td>$0.6552&nbsp;&nbsp;</td>
<td>-14.3%</td>
</tr>
<tr>
<td>Fartcoin (CRYPTO: FARTCOIN)</td>
<td>$0.8457</td>
<td>-7.4%</td>
</tr>
<tr>
<td>JasmyCoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">JASMY</a>)</td>
<td>$0.01322</td>
<td>-6.2%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto chart analyst Ali Martinez highlights Bitcoin being stuck between two major supply zones: $81,440 and $86,430, suggesting it needs a clean breakout to escape the range.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> <a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> is caught between two major supply zones: $81,440 and $86,430. <a href="https://t.co/x4e3sMu2nx">pic.twitter.com/x4e3sMu2nx</a>
&mdash; Ali (@ali_charts) <a href="https://twitter.com/ali_charts/status/1912626052117197013?ref_src=twsrc%5Etfw">April 16, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
More Crypto Online <a href="https://x.com/Morecryptoonl/status/1912923530934599760">points</a> out that volatility remains compressed, but price is edging closer to resistance. A break above yesterday's high could trigger a sharp rally to $87,900. For now, Bitcoin is still in a choppy, convictionless correction.
Altcoin Sherpa offers a bold outlook, saying he strongly believes Bitcoin will either blast through to $93,000 or drop into the high $70,000s in a single decisive move. He notes that Bitcoin has been ranging for nearly a month.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">man I have this weird feeling that <a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> either just blasts through to like 93k or dumps to high 70ks in 1 go. it&#39;s been in this trading range for a month <a href="https://t.co/f1sOrFZojE">pic.twitter.com/f1sOrFZojE</a>
&mdash; Altcoin Sherpa (@AltcoinSherpa) <a href="https://twitter.com/AltcoinSherpa/status/1912916404983959953?ref_src=twsrc%5Etfw">April 17, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Nebraskangooner <a href="https://x.com/Nebraskangooner/status/1912860665905107254">sees</a> Bitcoin consolidating above key support and believes if the current structure resolves upward, there&#8217;s a real chance of testing the $90,000+ resistance. 
Degengambleh <a href="https://x.com/degengambleh/status/1912897967981265399">offers</a> a dual-scenario outlook: either a &#8220;Green God Candle&#8221; breakout with no turning back, or one final shakeout before a face-melting rally to new highs. 
In either case, he believes the bottom is likely in and not just for Bitcoin, but for most meme coins as well.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44863580/bitcoin-stuck-below-85000-bull-run-shakeout-or-bearish-downtrend">Bitcoin Stuck Below $85,000: Bull Run Shakeout Or Bearish Downtrend?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$JASMY

$SHIB

$SOL

$XRP

Bitcoin, Ethereum, XRP, Dogecoin End Thursday In Green Ahead Of Easter Weekend

BancFirst (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BANF#NASDAQ">BANF</a>) reported quarterly earnings of $1.67 per share which beat the analyst consensus estimate of $1.58 by 5.7 percent. This is a 11.33 percent increase over earnings of $1.50 per share from the same period last year.

Earnings

Earnings Beats

BANF

BancFirst Q1 EPS $1.67 Beats $1.58 Estimate

Some designs age well. Others just get better with <a href="https://www.benzinga.com/topic/420">the season</a>.
Swatch&#8216;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SWGAY#OTC">SWGAY</a>) Up In Smoke, part of the BIG BOLD lineup, first dropped in September 2024, but lately it&#8217;s catching new attention—and for good reason. With its minty green tone, smoke graphics on the dial and ultra-chill BIOCERAMIC case, it feels like a gift made for a very specific kind of enthusiast.
Let's just say it fits the mood of April.
Built with a 47mm case and designed for those who like their style big and their energy relaxed, Up In Smoke isn't trying to scream anything—it just nods, slowly.
"It's a watch that invites you to sit back, relax and feel the buzz," says Swatch.
Cool, casual and not too obvious, it's the kind of timepiece that sparks curiosity without forcing the conversation. And while it might not have launched with this moment in mind, it's proving to be perfectly timed.
Still available via <a class="" href="https://www.swatch.com">Swatch.com</a> and select stores, this one's become a low-key standout in the brand's evolving catalog of playful, artful wristwear. Swatch has always understood the power of cultural timing—and this piece? It&#8217;s right on it.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/25/04/44871633/mike-tyson-cannabis-ceo-the-champ-now-runs-carma-holdco">Mike Tyson, Cannabis CEO: The Champ Now Runs Carma HoldCo</a></li>
</ul>
Photo courtesy of Swatch

Cannabis

SWGAY

Swatch's 'Up In Smoke' Watch Is The Low-Key Flex Of 4/20 Season

Eli Lilly &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) shares staged their sharpest single-day rally in nearly 25 years Thursday, after unveiling data from a pivotal trial that could cement its leadership in a weight-loss drug market projected to more than triple <a href="https://www.benzinga.com/general/biotech/25/04/44871681/lillys-diabetes-pill-clears-major-trial-analyst-points-to-global-potential">in size by 2030. </a>
The stock surged, closing the day up 14.36% to $839.96, marking its best performance since June 2000.
In a Thursday note, Goldman Sachs analyst Asad Haider, CFA said Eli Lilly's first Phase 3 trial of orforglipron — a once-daily oral treatment for type 2 diabetes and obesity — hit its top-line targets with best-case scenario results across weight loss, blood sugar control and safety.
<h1 class="wp-block-heading">The Data That Moved the Market</h1>
Lilly's ACHIEVE-1 trial evaluated orforglipron, an oral GLP-1 (glucagon-like peptide-1) receptor agonist, in adults with type 2 diabetes. 
At the highest 36mg dose, patients saw an average weight reduction of 7.9% over 40 weeks — translating to 16 pounds of weight loss, substantially above the placebo-adjusted rate of 6.3%.
For context, that outperforms Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) 's Rybelsus — currently the only oral GLP-1 treatment available — which achieved a 4.9% weight loss at its peak dosage in the SUSTAIN-1 trial.
In addition, orforglipron delivered A1C reductions of up to 1.6%, aligning with injectable semaglutide's performance and hitting a critical target in glycemic control. 
More than 65% of participants on the highest dose achieved an A1C level at or below 6.5%, a threshold defined by the American Diabetes Association as the benchmark for controlled diabetes.
Discontinuation due to side effects was 8% at the top dose, and there were no reported liver injury signals — two key safety indicators watched closely by investors after setbacks in rival studies.
<h1 class="wp-block-heading">Why Wall Street Is Cheering</h1>
Goldman Sachs analysts wrote that the trial marks "an important clearing event for LLY shares," especially after recent disappointments from rivals like Novo Nordisk A/S and Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) in their respective obesity pipelines. 
The investment bank reiterated a Buy rating and $888 price target on the stock, citing Lilly's potential to dominate a market expected to balloon from $28 billion today to $95 billion by 2030.
Their internal forecasts see risk-adjusted peak sales for orforglipron hitting $23.5 billion by 2035, with commercial rollout starting globally in 2026. That's well above the Street's consensus of $16.8 billion.
"This data trends toward our bull case scenario," Goldman said, noting that investor caution ahead of the binary trial event was likely keeping shares from rallying sooner.
<h1 class="wp-block-heading">Is Orforglipron The ‘Ozempic In A Pill'?</h1>
Tim Anderson, equity analyst at Bank of America, said Thursday's results were "pretty much a best-case scenario," covering all four key investor watchpoints: weight loss, blood sugar control, tolerability and safety.
Calling orforglipron a potential "Ozempic in a pill," Anderson highlighted its small molecule structure as a key differentiator. 
Unlike Novo's Rybelsus, which is a peptide with cold-chain storage limitations, orforglipron's easier manufacturing and oral delivery method could unlock demand in emerging markets, where injectables face logistical hurdles.
"Positive results like these, in a skittish market, should be received well," Anderson said, adding that the company remains one of the two dominant incumbents in the diabetes and obesity drug space.
Bank of America reiterated its Buy rating and $1,000 price objective, citing Eli Lilly's superior growth metrics: while the stock trades at roughly three times the average pharma price-to-earnings multiple, its expected earnings-per-share growth is five to six times higher than peers, making it relatively attractive on a PEG basis.
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44873779/wall-street-rebounds-eli-lilly-rallies-unitedhealth-group-plummets-whats-driving-markets-thursday">Wall Street Rebounds, Eli Lilly Rallies, UnitedHealth Group Plummets: What&#8217;s Driving Markets Thursday?</a></li>
</ul>

Biotech

Health Care

AMGN

Eli Lilly Rallies Over 14%, Notches Best Day Since June 2000 On Oral Weight-Loss Drug Results: Analysts React

The long-awaited flurry of fintech initial public offerings may have just gotten further delayed. This time, it&#8217;s due to a market selloff sparked by former President Donald Trump's <a href="https://www.benzinga.com/markets/25/04/44831287/trump-administration-imposes-up-to-245-tariff-on-chinese-imports-amid-intensifying-trade-battle">new trade tariffs</a>.
What Happened: According <a href="https://www.wsj.com/livecoverage/stock-market-tariffs-trade-war-04-04-2025/card/exclusive-klarna-pauses-planned-ipo-after-trump-tariff-turmoil-NMXYuKXzW6Xv4ao3CSxr">to</a> The Wall Street Journal, Klarna and Chime are both holding off on public listings. 
Just a day earlier, Plaid announced a $535 million capital raise at a $6 billion valuation—less than half its 2021 <a href="https://www.benzinga.com/markets/equities/24/02/37215731/ipo-revival-in-2024-plaid-chime-and-kim-kardashians-skims-among-potential-market-movers">peak of $13.5 billion</a>.
The signs are clear: for late-stage fintech companies, the public markets are no longer a welcome exit. Investors punished stocks this week, reacting sharply to tariff-related uncertainty, rising inflation expectations, and a risk-off shift.
Klarna, a consumer lending platform, had reportedly aimed for a $15 billion valuation. Chime, a mobile banking app, was targeting around $25 billion.
See Also: TK
Why It Matters: The recent selloff wasn't just a routine correction but a reaction to geopolitical tension. Trump's new tariffs spooked global investors, pulling tech and fintech stocks into a tailspin. That kind of volatility makes pricing new IPOs nearly impossible for underwriters.
Affirm Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>), often seen as Klarna's closest U.S. peer, fell more than 15% after the news. The market is once again de-risking, favoring cash flow and defensibility over growth-at-all-costs—a narrative many consumer fintech firms can't support right now.
After a brutal freeze in 2022 and 2023, fintech insiders had high hopes <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44875036/5-blockchain-ipos-to-watch-in-2025">for a 2025 revival</a>. Interest rates were stabilizing, inflation was cooling, and tech stocks rallied after Trump's <a href="https://www.benzinga.com/news/large-cap/24/11/41886058/donald-trump-victory-week-nov-4-8-these-large-cap-stocks-were-biggest-gainers">reelection in November</a>.
Early investors and employees at unicorns like Chime, Klarna, and Plaid were eager for liquidity after nearly a decade of staying private. On the buy-side, hedge funds, private equity, and crossover investors were showing fresh appetite for fintech, even scooping up under-the-radar deals in Q1.
It was shaping up to be a domino year—if one IPO popped, others like Stripe, Ramp, and Brex could follow.
But now, the opposite seems likely. With global markets tanking on fears of an escalating trade war, the IPO window is once again shut.
What&#8217;s Next: The message is clear for late-stage fintech startups: stay private longer. Companies that were expected to file S-1s this summer are now pursuing bridge rounds, structured equity, or flat-down private raises to buy more time.
But the clock is ticking. Investor pressure for exits is building, especially from employees holding illiquid equity. These companies will eventually need to go public—it's just a question of when, and how much pain they'll have to endure when they do.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44875406/hell-be-out-if-i-ask-him-can-trumps-threat-to-oust-powell-shake-the-fed">&#8216;He&#8217;ll Be Out&#8230; If I Ask Him&#8217;: Can Trump&#8217;s Threat To Oust Powell Shake The Fed?</a></li>
</ul>
Image: Shutterstock

Fintech news covering the emerging Financial Technology services sector

Fintech

IPOs

Tech

AFRM

Trump's Tariffs Just Slammed The IPO Window Shut For Fintech

BayCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCML#NASDAQ">BCML</a>) reported quarterly earnings of $0.51 per share which missed the analyst consensus estimate of $0.52 by 1.92 percent. This is unchanged from the same period last year.

Earnings Misses

BCML

BayCom Q1 EPS $0.51 Misses $0.52 Estimate

Billionaire hedge fund manager Bill Ackman posted his investment thesis for Hertz Global Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NYSE">HTZ</a>) on Thursday, one day after disclosing his fund, Pershing Square, had built a sizable stake in the<a href="https://www.benzinga.com/trading-ideas/movers/25/04/44876089/hertz-stock-is-racing-higher-thursday-whats-driving-the-action"> car rental company. </a>
The Details: Ackman confirmed a previous CNBC report that Pershing Square now holds a 19.8% stake in Hertz, making the fund the company's second-largest shareholder.&nbsp;
Read Next:<a href="https://www.benzinga.com/general/health-care/25/04/44869920/unitedhealth-ceo-says-high-cost-of-us-health-care-simply-not-sustainable"> UnitedHealth CEO Says High Cost Of US Health Care &#8216;Simply Not Sustainable&#8217;&nbsp;</a>
In a <a href="https://x.com/BillAckman/status/1912955549542744462">post </a>on X, the hedge fund manager pointed to several factors he believes make Hertz an attractive investment:
"We believe that a combination of: (1) an improving industry structure and more rational competitive behavior, (2) the near resolution of the company's over exposure to Teslas, (3) a successful operational turnaround plan under a new management team with a track record of success in an adjacent industry, and (4) the company's leveraged capital structure will enable Hertz shareholders to generate a highly attractive return on investment," Ackman wrote. 
He highlighted Enterprise as an industry leader and said his firm estimates that Enterprise has profit margins of 20% or higher, demonstrating the potential for large profits in the car rental industry. 
Ackman closed the post with a proposed scenario in which Hertz could potentially partner with Uber Technologies, Inc. (NYSE: UBER) on an autonomous vehicle fleet. 
"Hertz's large installed fleet of 500k vehicles, its expertise in vehicle maintenance and servicing, and the significant scope and scale of its thousands of locations (11,200 globally) and other difficult to replace at scale physical infrastructure make it an ideal partner for @Uber, a partnership which could greatly improve the utilization and profitability of Hertz's vehicle fleet," Ackman wrote.&nbsp;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">We began accumulating shares in <a href="https://twitter.com/Hertz?ref_src=twsrc%5Etfw">@Hertz</a> late last year, and as of today, we have a 19.8% stake in the company comprised of outright share ownership and total return swaps. Hertz can be thought of as an operating company combined with a highly leveraged portfolio of automobiles.…
&mdash; Bill Ackman (@BillAckman) <a href="https://twitter.com/BillAckman/status/1912955549542744462?ref_src=twsrc%5Etfw">April 17, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/social-media/25/04/44817229/chinese-tiktok-influencers-expose-cheap-nike-lululemon-suppliers-to-bypass-trump-tariffs">Chinese TikTok Influencers &#8216;Expose&#8217; Cheap Nike, Lululemon Suppliers To Bypass Trump Tariffs&nbsp;</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Social Media

General

UBER

Billionare Investor Bill Ackman Posts Hertz Investment Thesis, Proposes AV Fleet Partnership With Uber

Dividends

Bar Harbor Bankshares Increases Quarterly Dividend From $0.30 To $0.32

€303.4 Million EPC Solar Projects to Enhance Romania's Renewable Energy Initiatives and Reduce Carbon Emissions
Ameresco SUNEL Energy SA, a joint venture between <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fameresco.com%2F&amp;esheet=54239972&amp;newsitemid=20250417569645&amp;lan=en-US&amp;anchor=Ameresco%2C+Inc.&amp;index=1&amp;md5=6eb9771f96931c85421bfcb20875b3aa">Ameresco, Inc.</a>, (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMRC#NYSE">AMRC</a>), a leading energy solutions provider dedicated to helping customers navigate the energy transition, and SUNEL Group, an international solar PV EPC contractor, today announced €303.4 million EPC Contracts for three solar parks located in the southwestern region of Romania. These 466 MWp solar projects represent a major milestone in Romania's journey towards enhancing its energy security, fostering economic growth, and meeting its climate commitments. It will replace coal-fired power generation and bolster the nation's commitment to phasing out coal by 2032.
As the Engineering, Procurement, and Construction (EPC) contract provider, Ameresco SUNEL Energy SA is dedicated to ensuring the highest efficiency and environmental standards. Ameresco SUNEL Energy SA will oversee the design, procurement, construction, commissioning, operation, and maintenance.
Construction of the projects is expected to be completed within 18 months, bringing Romania closer to its renewable energy targets while strengthening its position as a regional leader in the transition to clean energy.
 &nbsp;

Contracts

AMRC

Ameresco SUNEL Energy Secures €303.4M EPC Contracts For Three Solar Parks Located In Southwestern Region Of Romania

Bar Harbor Bankshares (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BHB#AMEX">BHB</a>) reported quarterly earnings of $0.68 per share which met the analyst consensus estimate. This is a 3.03 percent increase over earnings of $0.66 per share from the same period last year. The company reported quarterly sales of $37.92 million which missed the analyst consensus estimate of $39.12 million by 3.06 percent. This is a 3.50 percent increase over sales of $36.64 million the same period last year.

Comments

Bausch & Lomb

Notizie

Ultime notizie per Bausch & Lomb (NYSE:BLCO) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO